WaveMan · Form 4
Ra Capital Management, L.P. insider trades
> Search tickers & screens ⌘K
LIVE

Ra Capital Management, L.P. insider trades

Ra Capital Management, L.P. has filed 73 Form 4s with the SEC that we hold, for Artiva Biotherapeutics, Inc. (ARTV) (Director, 10% owner), Vor Biopharma Inc. (VOR) (10% owner), Wave Life Sciences, Inc. (WVE) (Director, 10% owner) and Mineralys Therapeutics, Inc. (MLYS) (Director), among 33 companies in all. Across all of them we count 57 purchases worth $363.2M and 50 sales worth $88.0M reported on Form 4. In the last 12 months: 31 purchases ($93.6M) and 50 sales ($88.0M). The largest single trade was a purchase of 5,161,290 shares of Acumen Pharmaceuticals, Inc. worth $40.0M, dated 2023-07-21. Of 2 sales filed since we began reading the 10b5-1 checkbox, 0 (0%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-08-18 and the latest 2026-10-07.

Artiva Biotherapeutics, Inc. (ARTV)

Director, 10% owner · 10 filings · 13 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-06-25P, purchase reported on Form 431,000$275.3K2026-06-29
2026-06-26P, purchase reported on Form 41,876$16.8K2026-06-29
2026-07-10P, purchase reported on Form 415,102$135.5K2026-07-14
2026-07-13P, purchase reported on Form 46,522$58.3K2026-07-23
2026-07-13P, purchase reported on Form 46,552$58.6K2026-07-14
2026-07-16P, purchase reported on Form 4152,472$1.4M2026-07-20
2026-07-17P, purchase reported on Form 47,882$70.5K2026-07-20
2026-07-21P, purchase reported on Form 4120,582$1.2M2026-07-23
2026-07-22P, purchase reported on Form 484,124$835.4K2026-07-23
2026-07-23P, purchase reported on Form 459,880$596.4K2026-07-23
2026-07-24P, purchase reported on Form 441,319$412.8K2026-07-28
2026-07-29P, purchase reported on Form 420,824$208.0K2026-07-31
2026-07-31P, purchase reported on Form 424,944$247.7K2026-07-31

Vor Biopharma Inc. (VOR)

10% owner · 9 filings · 9 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-10-23S, sale reported on Form 476,880$2.2M2025-10-27
2025-10-24S, sale reported on Form 453,345$1.5M2025-10-27
2025-10-27S, sale reported on Form 490,941$2.6M2025-10-27
2026-04-13S, sale reported on Form 4530,610$8.6M2026-04-15
2026-04-14S, sale reported on Form 4153,735$2.5M2026-04-15
2026-04-15S, sale reported on Form 453,644$858.8K2026-04-15
2026-04-17S, sale reported on Form 4458,411$7.5M2026-04-21
2026-04-20S, sale reported on Form 4171,963$2.7M2026-04-21
2026-07-16S, sale reported on Form 4213$4.2K2026-07-21

Wave Life Sciences, Inc. (WVE)

Director, 10% owner · 7 filings · 6 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-12-11P, purchase reported on Form 41,000,000$5.0M2024-01-17
2025-11-13P, purchase reported on Form 41,000$6.7K2025-11-14
2026-03-26P, purchase reported on Form 4351,224$2.2M2026-03-30
2026-03-26P, purchase reported on Form 44,954,558$30.0M2026-03-30
2026-03-27P, purchase reported on Form 42,495,623$16.0M2026-03-30
2026-03-30P, purchase reported on Form 4971,091$6.3M2026-03-30

Mineralys Therapeutics, Inc. (MLYS)

Director · 4 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2025-09-04P, purchase reported on Form 41,176,470$30.0M2025-09-08

Tyra Biosciences, Inc. (TYRA)

Director, 10% owner · 4 filings · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-06-12P, purchase reported on Form 431,307$319.3K2025-06-16
2025-06-13P, purchase reported on Form 4120,167$1.2M2025-06-16
2025-06-16P, purchase reported on Form 411,813$119.7K2025-06-16

Werewolf Therapeutics, Inc. (HOWL)

10% owner · 4 filings · 14 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-05-08S, sale reported on Form 4351,514$249.6K2026-05-12
2026-05-08S, sale reported on Form 425,012$17.8K2026-05-12
2026-05-11S, sale reported on Form 45,812$3.9K2026-05-12
2026-05-11S, sale reported on Form 481,678$54.7K2026-05-12
2026-05-12S, sale reported on Form 46,719$4.3K2026-05-12
2026-05-12S, sale reported on Form 494,432$60.4K2026-05-12
2026-06-12S, sale reported on Form 4159,119$63.6K2026-06-16
2026-06-12S, sale reported on Form 411,322$4.5K2026-06-16
2026-06-15S, sale reported on Form 4120,216$46.9K2026-06-16
2026-06-15S, sale reported on Form 48,554$3.3K2026-06-16
2026-06-16S, sale reported on Form 4139,686$51.7K2026-06-16
2026-06-16S, sale reported on Form 49,939$3.7K2026-06-16
2026-06-17S, sale reported on Form 4389,216$136.2K2026-06-22
2026-06-17S, sale reported on Form 427,695$9.7K2026-06-22

Sionna Therapeutics, Inc. (SION)

Director, 10% owner · 3 filings · 28 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-02-10P, purchase reported on Form 41,022,586$18.4M2025-02-10
2025-02-10P, purchase reported on Form 4102,414$1.8M2025-02-10
2025-11-17S, sale reported on Form 453$2.2K2025-11-19
2025-11-17S, sale reported on Form 4433$18.2K2025-11-19
2025-11-17S, sale reported on Form 4280$11.8K2025-11-19
2025-11-17S, sale reported on Form 4331$13.9K2025-11-19
2025-11-17S, sale reported on Form 410,707$439.5K2025-11-19
2025-11-17S, sale reported on Form 49,063$372.0K2025-11-19
2025-11-17S, sale reported on Form 413,964$573.2K2025-11-19
2025-11-17S, sale reported on Form 41,701$69.8K2025-11-19
2025-11-17S, sale reported on Form 413,734$552.1K2025-11-19
2025-11-17S, sale reported on Form 411,626$467.4K2025-11-19
2025-11-17S, sale reported on Form 417,913$720.1K2025-11-19
2025-11-17S, sale reported on Form 42,182$87.7K2025-11-19
2025-11-18S, sale reported on Form 41,770$70.0K2025-11-19
2025-11-18S, sale reported on Form 42,728$107.9K2025-11-19
2025-11-18S, sale reported on Form 4332$13.1K2025-11-19
2025-11-18S, sale reported on Form 42,092$82.8K2025-11-19
2025-11-19S, sale reported on Form 49$3652025-11-19
2025-11-19S, sale reported on Form 48$3252025-11-19
2025-11-19S, sale reported on Form 412$4872025-11-19
2025-11-19S, sale reported on Form 42$812025-11-19
2025-11-19S, sale reported on Form 414,325$573.1K2025-11-19
2025-11-19S, sale reported on Form 412,126$485.2K2025-11-19
2025-11-19S, sale reported on Form 418,684$747.5K2025-11-19
2025-11-19S, sale reported on Form 42,276$91.1K2025-11-19
2026-09-17S, sale reported on Form 43,415,011$21.6M2026-09-21
2026-09-17S, sale reported on Form 433,800$252.1K2026-09-21

ARS Pharmaceuticals, Inc. (SPRY)

Director, 10% owner · 2 filings · 4 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-08-29P, purchase reported on Form 43,750,000$23.2M2023-08-31
2024-03-25P, purchase reported on Form 4437,600$4.0M2024-03-27
2024-03-26P, purchase reported on Form 4457,745$4.4M2024-03-27
2024-03-27P, purchase reported on Form 4505,954$5.0M2024-03-27

Bicara Therapeutics Inc. (BCAX)

Director, 10% owner · 2 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2026-02-26P, purchase reported on Form 4300,000$4.8M2026-03-02

Climb Bio, Inc. (CLYM)

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Fulcrum Therapeutics, Inc. (FULC)

10% owner · 2 filings · 4 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-12-14P, purchase reported on Form 4824,600$4.5M2022-12-16
2022-12-15P, purchase reported on Form 4237,029$1.3M2022-12-16
2022-12-16P, purchase reported on Form 41,341,420$7.3M2022-12-16
2023-01-20P, purchase reported on Form 41,923,076$25.0M2023-01-24

Hemab Therapeutics Holdings, Inc. (COAG)

10% owner · 2 filings · 4 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-05-19P, purchase reported on Form 43,802$94.9K2026-05-21
2026-05-20P, purchase reported on Form 4996$24.8K2026-05-21
2026-06-15P, purchase reported on Form 46,146$153.0K2026-06-17
2026-06-16P, purchase reported on Form 461,523$1.5M2026-06-17

Nkarta, Inc. (NKTX)

Director, 10% owner · 2 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2024-03-27P, purchase reported on Form 43,000,000$30.0M2024-03-29

4D Molecular Therapeutics, Inc. (FDMT)

10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Acrivon Therapeutics, Inc. (ACRV)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Acumen Pharmaceuticals, Inc. (ABOS)

Director, 10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-07-21P, purchase reported on Form 45,161,290$40.0M2023-07-25

Black Diamond Therapeutics, Inc. (BDTX)

Director · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-07-05P, purchase reported on Form 4935,850$4.7M2023-07-07

CDTX

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Cytek Biosciences, Inc. (CTKB)

Director · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-02-14P, purchase reported on Form 4166,229$2.4M2022-02-16
2022-02-15P, purchase reported on Form 4166,200$2.5M2022-02-16
2022-02-16P, purchase reported on Form 4166,200$2.5M2022-02-16

DICE

Director, 10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-03-23P, purchase reported on Form 4155,089$4.1M2023-03-27
2023-03-24P, purchase reported on Form 4192,335$5.2M2023-03-27
2023-03-27P, purchase reported on Form 4151,132$4.2M2023-03-27

ETNB

Director, 10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-03-24P, purchase reported on Form 42,461,538$40.0M2023-03-30

Enliven Therapeutics, Inc. (IMRA)

10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-01-03P, purchase reported on Form 4629,297$2.5M2023-01-05

Evommune, Inc. (EVMN)

Director, 10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-11-07P, purchase reported on Form 41,157,096$18.5M2025-11-12
2025-11-07P, purchase reported on Form 492,904$1.5M2025-11-12

FTMX

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Freenome, Inc. (FRNM)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Inhibikase Therapeutics, Inc. (IKT)

10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Jade Biosciences, Inc. (AVTE)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Janux Therapeutics, Inc. (JANX)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

LENZ Therapeutics, Inc. (LENZ)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Parabilis Medicines, Inc. (PBLS)

Director, 10% owner · 1 filing · 6 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-07-20P, purchase reported on Form 498,433$2.7M2026-07-22
2026-07-20P, purchase reported on Form 432,987$914.4K2026-07-22
2026-07-21P, purchase reported on Form 421,696$606.6K2026-07-22
2026-07-21P, purchase reported on Form 46,504$189.7K2026-07-22
2026-07-21P, purchase reported on Form 437,723$1.1M2026-07-22
2026-07-22P, purchase reported on Form 447,250$1.4M2026-07-22

PepGen Inc. (PEPG)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Septerna, Inc. (SEPN)

Director, 10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2026-08-12S, sale reported on Form 4746,500$31.7M2026-08-14

Solid Biosciences Inc. (SLDB)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1346824) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms